Biotechnology

Elevation Oncology

Elevation Oncology Terminates License Agreement With CSPC Megalith Biopharmaceutical

FactSet: Elevation Oncology rated as Hold

William Blair downgrades Elevation Oncology rating

Elevation Oncology and Concentra Biosciences Sign Merger Agreement

Elevation Oncology released FY2025 Q1 earnings on May 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.2401 (forecast USD -0.1925)

ELEVATION ONCOLOGY target price downgraded to $0.5

Elevation Oncology Reports Expanded Net Loss in Q1 2025

Elevation Oncology Inc. fulfills loan obligations with K2 HealthVentures

Elevation Oncology Inc Expected to Report a Loss of 19 Cents Per Share

Elevation Oncology Presents EO-1022 Preclinical Data

Elevation Oncology Inc Early Repayment of $30 Million Term Loan

Stephens & Co. Downgrades Elevation Oncology Rating to Hold, Target Price Adjusted to $1.00

Citizens Capital Markets Downgrades Elevation Oncology Rating to Market Perform

Analysts rate Elevation Oncology as 'buy' with a price target of $1.86

Elevation Oncology Suspends EO-3021 Gastric Cancer Development and Cuts 70% of Workforce

Elevation Oncology released FY2024 Annual Earnings on March 6 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.7766 USD (forecast -0.8537 USD)

Elevation Oncology released FY2024 Q4 earnings on March 6 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.1765 USD (forecast -0.2225 USD)

Elevation Oncology Announces Targeted Cancer Treatment Plan in Boston

Elevation Oncology released FY2024 9 Months Earnings on November 6, 2024 (EST) with actual revenue of USD 0 and EPS of USD -0.6018

Elevation Oncology released FY2024 Q3 earnings on November 6 (EST), actual revenue $0 (forecast $0), actual EPS -0.2179 (forecast -0.2)

AMC Robotics

Radiopharm Theranostics

Artiva Biotherapeutics

Netclass Tech

3 E Network Tech

Quipt Home Medical

Kaixin

Ascent Solar Tech

Click Holdings/BVI

Climb Bio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap